Articles from Turn Therapeutics

LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced the appointment of Andrew Scott as Vice President of Corporate Communications. In this new role, Mr. Scott will oversee investor relations, capital markets strategy, and corporate communications, while supporting the Company’s licensing and partnership initiatives.

Agreement combines Turn’s PermaFusion® delivery platform with Medline’s global scale and distribution capabilities to advance professional and retail product opportunities

Company to host shareholder webinar today, October 22, 2025, at 2:00 PM ET to review execution milestones, pipeline progress, and capital strategy

LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming Founder Blog authored by patient-turned-founder and CEO, Bradley Burnam.

Seasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease research

Veteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programs

Founder & CEO, Bradley Burnam, to Ring NASDAQ “Closing Bell” at 4:00 PM ET

Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing dermatology, wound care, and anti-infective therapies, today announced that it expects its common stock will begin trading on the Nasdaq Global Market under the ticker symbol “TTRX” on October 8, 2025.

Turn Therapeutics®, a clinical-stage biotechnology company focused on dermatology, wound care, and infectious disease, today announced it will host a live, Open Investor Session on Wednesday, September 17. The webcast will be live-streamed at turntherapeutics.com/open-investor-session, with a recording available to follow on the company's website.

Turn Therapeutics today announced promising stability data for its intranasal vaccine candidate, marking a significant step toward potentially reducing dependency on ultra-cold vaccine storage. The live, lipid-enveloped vaccine demonstrated 14 days of viability at ambient temperature and 28 days under standard refrigeration.

Turn Therapeutics today announced the initiation of a randomized, double-blind, vehicle-controlled clinical trial evaluating its topical GX-03 formulation -- previously used in the company's advanced wound care product Hexagen -- for the treatment of moderate-to-severe eczema (atopic dermatitis). Patient dosing commenced on July 11 in Dallas.

Turn Therapeutics, a clinical-stage pharmaceutical and medical device company, announced today that it has achieved a critical milestone in its effort to reduce dependency on cold-storage for vaccines.

Turn Therapeutics, a clinical-stage biotechnology company pioneering next-generation topical therapies, today announced the launch of its final crowdfund investment round in tandem with the upcoming initiation of a controlled clinical trial evaluating its flagship, non-steroidal topical platform in patients with moderate to severe eczema.

Turn Therapeutics has successfully maintained a live vaccine's viability for 24 hours at room temperature using its oil suspension technology. This breakthrough -- which entailed stabilizing a well-recognized vaccine vector in a viscous oil delivery system -- is a step toward making it easier to store, transport, and administer vaccines globally, especially in regions with limited infrastructure for refrigerated and deep-freeze vaccine storage.

Turn Therapeutics, an innovator in advanced wound and dermatology solutions, is pleased to announce a significant investment commitment from GEM Global Yield LLC SCS ("GEM"), a $3.4 billion private equity and alternative investment group.

In a widely cited in-vivo model of atopic dermatitis, Turn Therapeutics' atopic dermatitis candidate showed a dramatic reduction in disease severity versus placebo.

Turn Therapeutics, an innovative biotech company, launched its first public investment campaign today to fund clinical trials of its Food and Drug Administration-cleared antimicrobial ointment for two potential new drug indications: moderate to severe eczema and onychomycosis, or toenail fungus.

Turn Therapeutics, a biotechnology company specializing in advanced wound care and infection control, today announced the results of its Phase 2B, placebo controlled trial of Hexagen Antimicrobial Ointment in treating mild to moderate infected COVID-19 patients. This double-blinded study enrolled 80 people across three sites in Panama to evaluate safety and efficacy of Hexagen Antimicrobial as an early intervention against COVID-19. Specifically, the study investigated intranasal use of FDA-cleared Hexagen immediately post-positive PCR test as a means to reduce disease duration, as well as the safety of consistent intranasal use of Hexagen over 5 and 10 days. Efficacy results have confirmed in-vitro virucidal data, while safety results have confirmed in-vivo biocompatibility data for use on mucous membranes.